Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE)

Clinical and Experimental Immunology

Volumn 109, Issue 1, 1997, Pages 20-26

  Takeuchi, T ^a,b   Pang, M ^a   Amano, K ^a   Koide, J ^a   Abe, T ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Signal transduction; T cell receptor; Tyrosine kinase; Tyrosine phosphorylation

Indexed keywords

CD45 ANTIGEN; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INFLAMMATORY DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION;

EID: 0030848150     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4371334.x     Document Type: Article

References (54)

1. Cohen PL. T- and B-cell abnormalities in systemic lupus. J Invest Dermatol 1993; 100:69S-72S.
2. Steinberg AD. Systemic lupus erythematosus: theories of pathogenesis and approach to therapy. Clin Immunol Immunopathol 1994; 72:171-6.
3. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93-151.
4. Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. Annu Rev Immunol 1993; 11:79-104.
5. Boumpas DT, Fessler BJ, Austin HAr et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologie and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123:42-53.
6. Ebling FM, Hahn BH. Pathogenic subsets of antibodies to DNA. Int Rev Immunol 1989; 5:79-95.
7. Tsokos GC. Lymphocytes, cytokines, inflammation, and immune trafficking. Curr Opin Rheumatol 1994; 6:461-7.
8. Belmont HM, Abranson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996; 39:9-22.
9. Samelson LE, Davidson WF, Morse HCI et al. Abnormal tyrosine phosphorylation on T-cell receptor in lymphoproliferative disorders. Nature 1986; 324:674-6.
10. - T cells of mice with a lymphoproliferative disorder [published erratum appears in Proc Natl Acad Sci USA 1990; 87:2865]. Proc Natl Acad Sci USA 1989; 86:10064-8.
11. Altman A. Abnormal antigen receptor-initiated signal transduction in Ipr T lymphocytes. Semin Immunol 1994; 6:9-17.
12. Dayal AK, Kammer GM. The T cell enigma in lupus. Arthritis Rheum 1996; 39:23-33.
13. Takeuchi T, Tanaka S, Steinberg AD et al. Defective expression of the 2H4 molecule after autologous mixed lymphocyte activation in systemic lupus erythematosus patients. J Clin Invest 1988; 82:1288-94.
14. Hunter T. Protein-tyrosine phosphatases: the other side of the coin. Cell 1989; 58:1013-6.
15. Johnson P, Ostergaard HL, Wasden C et al. Mutational analysis of CD45. A leukocyte-specific protein tyrosine phosphatase. J Biol Chem 1992; 267:8035-41.
16. Streuli M, Saito H. Regulation of tissue-specific alternative splicing: exon-spedfic cis-elements govern the splicing of leukocyte common antigen pre-mRNA. Embo J 1989; 8:787-96.
17. Thomas ML. The leukocyte common antigen family. Annu Rev Immunol 1989; 7:339-69.
18. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76:263-74.
19. Samelson LE, Klausner RD. Tyrosine kinases and tyrosine-based activation motifs. Current research on activation via the T cell antigen receptor. J Biol Chem 1992; 267:24913-6.
20. Chan AC, Desai DM, Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol 1994; 12:555-92.
21. Tan EM, Cohen AS. Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
22. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.
23. Takeuchi T, Amano K, Sekine H et al. Upregulated expression and function of integrin adhesive receptors in systemic lupus erythematosus patients with vasculitis. J Clin Invest 1993; 92:3008-16.
24. Takeuchi T, Rudd CE, Tanaka S, Rothstein DM. Schlossman SF, Morimoto C. Functional characterization of the CD45R (2H4) molecule on CD8 (T8) cells in the autologous mixed lymphocyte reaction system. Eur J Immunol 1989; 19:747-55.
25. Ostergaard HL, Trowbridge IS. Negative regulation of CD45 protein tyrosine phosphatase activity by ionomycin in T cells. Science 1991; 253:1423-5.
26. Peyron J-F, Verma S, Malefyt RDW et al. The CD45 protein tyrosine phosphatase is required for the completion of the activation program leading to lymphokine production in the Jurkat human T cell line. Int Immunol 1991; 3:1357-66.
27. Huang YP, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986; 137:3515-20.
28. Monostori E, Hartyani Z, Ocsovszky I et al. Effect of phytohaemagglutinin on CD45 in T cells. Immunol Letters 1994; 42:197-201.
29. Katagiri C, Kawamura T, Matsuzawa S et al. Increases in protein phosphatase 2B activity in lymphoid tissues and T-lymphocytes of autoimmune MRL/MpJ-Ipr/Ipr mice. J Biochem Tokyo 1993; 114:874-8.
30. + T cells. Eur J Immunol 1995; 25:1399-404.
31. Sierakowski S, Kucharz EJ, Lightfoot RW et al. Impaired T-cell activation in patients with systemic lupus erythematosus. J Clin Immunol 1989; 9:469-76.
32. Blasini AM, Stekman IL, Gonzalez F et al. T lymphocytes from patients with systemic lupus crythematosus show increased response to interleukin-2 after costimulation with OKT3 monoclonal antibody and phorbol esters. Clin Immunol Immunopathol 1994; 70:66-72.
33. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995; 155:2269-81.
34. Tada Y, Nagasawa K, Yamauchi Y et al. A defect in the protein kinase C system in T cells from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1991; 60:220-31.
35. Kammer GM, Khan JU, Malemud CJ. Deficient type I protein kinase A isozyme activity in systemic lupus erythematosus T lymphocytes. J Clin Invest 1994; 94:422-30.
36. Trowbridge IS. CD45. A prototype for transmembrane protein tyrosine phosphatases. J Biol Chem 1991; 266:23517-20.
37. Furukawa T, Itoh M, Krueger NX et al. Specific interaction of the CD45 protein-tyrosine phosphatase with tyrosine-phosphorylatcd CD3 zeta chain. Proc Natl Acad Sci USA 1994; 91:10928-32.
38. Pingel JT, Thomas ML. Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferation. Cell 1989; 58:1055-65.
39. Koretzky GA, Picus J, Thomas ML et al. Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway. Nature 1990; 346:66-68.
40. 2+ oscillations. J Exp Med 1992; 176:8.35-44.
41. tyn couples the T cell antigen receptor to pathways of diacylglycerol production, protein kinase C activation and calcium influx. Embo J 1942; 11:4887-97.
42. Koretzky GA, Kohmetscher MA, Kadleck T et al. Restoration of T cell receptor-mediated signal transduction by transfection of CD45 cDNA into a CD45-deficient variant of the Jurkat T cell line. J Immunol 1992; 149:1138-42.
43. Volarevic S, Niklinska BB, Burns CM et al. Regulation of TCR signaling by CD45 lacking transmembrane and extracellular domains. Science 1993; 260:541-4.
44. Hovis RR, Donovan JA, Musci MA et al. Rescue of signaling by a chimeric protein containing the cytoplasmic domain of CD45. Science 1993; 260:544-6.
45. Desai DM, Sap J, Silvennoinen O et al. The catalytic activity of the CD45 membrane-proximal phosphatase domain is required for TCR signaling and regulation. Embo J 1994; 13:4002-10.
46. Thude H, Hundrieser J, Wonigeit K et al. A point mutation in the human CD45 gene associated with defective splicing of exon A. Eur J Immunol 1995; 25:2101-6.
47. Ostergaard HL, Shackelford DA, Hurley TR et al. Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines. Proc Natl Acad Sci USA 1989; 86:8959-63.
48. Czyzyk J, Fernsten P, Shaw M et al. Cell-type specificity of anti-CD45 autoantibodies in systemic lupus erythematosus. Arthritis Rheum 1996; 39:592-9.
49. Yamada A, Streuli M, Saito H et al. Effect of activation of protein kinase C on CD45 isoform expression and CD45 protein tyrosine phosphatase activity in T cells. Eur J Immunol 1990; 20:1655-60.
50. Stover DR, Charbonneau H, Tonks NK et al. Protein-tyrosine-phosphatase CD45 is phosphorylated transiently on tyrosine upon activation of Jurkat T cells. Proc Natl Acad Sci USA 1991; 88:7704-7.
51. Desai DM, Sap J, Schlessinger J et al. Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell 1993; 73:541-54.
52. Lokeshwar VB, Bourguignon LY. Tyrosine phosphatase activity of lymphoma CD45 (GP180) is regulated by a direct interaction with the cytoskeleton. J Biol Chem 1992; 267:21551-7.
53. Iida N, Lokeshwar VB, Bourguignon LY. Mapping the fodrin binding domain in CD45, a leukocyte membrane-associated tyrosine phosphatase. J Biol Chem 1994; 269:28576-83.
54. lck tyrosine kinase and activates the phosphatase. Mol Cell Biol 1994; 14:1308-21.